The associate vice president of neuroscience, US Medical Affairs at Eli Lilly discussed the complexities of migraine treatment, highlighting the need to address communication barriers between healthcare providers and patients. [WATCH TIME: 5 minutes]
In a phase 3 study and open-label extension, patients treated with daxibotulinumtoxinA showed significant improvements in their condition, explained by changes on the Toronto Western Spasmodic Torticollis Rating Scale.
The associate professor of pediatrics in neurology and epilepsy at Northwestern University Feinberg School of Medicine discussed the FDA-cleared phase 1/2 trial of an exon 50 skipping therapy to address the specific mutations causing Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]
In addition to showing a safe and tolerable safety profile, patients who underwent the procedure showed a 7-point median improvement on the upper extremity Fugl-Meyer Assessment when used in combination with physical rehabilitation.
The phase 2 clinical trial ACTIVATE investigating BIA 28-6156 for Parkinson disease is currently screening for patients in North America and with the Europe-based study beginning sometime during the third quarter of 2023.
Results indicated a substantial direct effect of air pollution on dementia suggesting that air pollution affects the development of dementia through multiple pathways.
The undergraduate program director at the University of South Carolina discussed the shift in teaching strategies for those in neurology and why more hands-on experience serves students better. [WATCH TIME: 5 minutes]
Stroke of an undetermined cause was associated with acute symptomatic seizures, an effect that was marginally mediated by cerebral microbleeds.
The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the dilemma of stratifying patients with Parkinson disease based on various criteria and emphasized the need for a consensus on classification. [WATCH TIME: 3 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Patients treated with the neuromodulation device outperformed those on placebo on several key outcomes, including Visual Analog Scale and Migraine-Specific Quality of Life Questionnaire scores.
The associate vice president of neuroscience, US Medical Affairs at Eli Lilly discussed the Think Talk Treat Migraine program which encourages both medical professionals and patients to identify migraine's effects. [WATCH TIME: 4 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology.
The majority of patients with ALS lack a monogenic mutation, with only 15-20% of patients having a disease that is driven and controlled by a single gene.
UB-311 elicited a robust, rapid, and titrated antibody response to amyloid-ß, with an overall 97% responder rate that was maintained by 93% of the cohort by the end of the 78-week study.
Neurology News Network for the week ending August 12, 2023. [WATCH TIME: 3 minutes]
Since it was first discovered in the early 1900s, the therapeutic approaches to treating myasthenia gravis have changed significantly, with several proven treatment options.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 11, 2023.
Prior research shows that a significant loss of the hypocretin-producing neurons, an increase in the histaminergic neurons, and contradicting signs of gliosis in the hypothalamus among patients with narcolepsy type 1.
The associate vice president of neuroscience, US Medical Affairs at Eli Lilly talked about the impact of migraine on women and the importance of primary care in managing this widespread condition. [WATCH TIME: 4 minutes]
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Thomas Crawford, MD. [LISTEN TIME: 24 minutes]
BridgeBio Pharma met with the FDA to discuss the use of glycosylated α-dystroglycan levels as a surrogate end point for its phase 3 trial FORTIFY investigating BBP-418 and believes there is the potential for an accelerated approval.
Pharmacokinetic results indicated that ACD856 has a suitable pharmacokinetic profile for further development with a rapid absorption, dose-dependent exposure, and a favorable metabolic profile.
The professor of anesthesiology at Washington University in St. Louis provided perspective on the respect and approach that comes with conducting research in underserved or impoverished communities. [WATCH TIME: 4 minutes]
The double-blind, placebo-controlled trial assesses change from baseline in the weekly average of daily self-reported worst pain intensity scores after 14 weeks of treatment.
The director of movement disorders at the Banner Sun Health Research Institute talked about alternative approaches for treating essential tremor beyond medications, and developments in the diagnostic criteria for Lewy body disorders. [WATCH TIME: 5 minutes]
Catch up on any of the neurology news headlines you may have missed over the course of July 2023, compiled all into one place by the NeurologyLive® team.
Patients who continued on active treatment into the open-label extension saw continued improvements in their condition after 14 weeks.
Results showed that 67% of treated patients in Stage A demonstrated evidence of clinical improvement, indicating that IgG autoantibodies play a significant role in the underlying biology of CIDP.
The executive vice president of the National MS Society provided insight on the Pathways to Cures roadmap, a global initiative to stop multiple sclerosis, restore function, and end MS.
